Apellis Pharmaceuticals, Inc. APLS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

48/100

1/7 Pass

SharesGrow Intrinsic Value

Apellis Pharmaceuticals, Inc. (APLS) 报告总资产为 $1.08B 总负债为 $705.11M 財年 2025, 总权益为 $370.15M.

公司持有 $467.76M 现金及短期投资. 总债务为 $486.31M, 净债务为 $18.55M. D/E比率为 1.31 (适中的).

流动比率为 3.14, 表明短期流动性强. 利息覆蓋率为 1.3x (weak).

本页支持的标准:

HEALTH (50/100, Partial) — 部分指标尚可但未全部达到理想水准
MOAT (65/100) — 总资产 $1.08B 和 equity $370.15M 支持公司的竞争规模
VALUE (18/100) — Debt-to-Equity 1.31 影响整体估值风险评估

SharesGrow 收入评分: 48/100 其中 1/7 项标准通过.

SharesGrow 7-Criteria Score

48/100

SG Score

View full scorecard →

✗

价值

18/100

Price-to-Earnings & upside

→ Valuation

未來

49/100

Analyst consensus

→ Forecast

✗

过去

25/100

→ Income

健康

50/100

Debt-to-Equity & liquidity

Proven by this page

护城河

65/100

→ Income

✓

成长

100/100

→ Income

✗

收入

30/100

→ Income

Apellis Pharmaceuticals, Inc. 资产负债表历史

指标	FY2025	FY2024	FY2023	FY2022
总资产	$1.08B	$885.05M	$788.73M	$760.22M
Total Liabilities	$705.11M	$656.51M	$594.21M	$590.35M
总债务	$486.31M	$469.78M	$110.93M	$112.71M
Cash & Investments	$467.76M	$411.29M	$352.3M	$551.8M
股东权益总计	$370.15M	$228.54M	$194.52M	$169.87M